Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes.
Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes. Enclomiphene is the trans-isomer of clomiphene, which is about a 60-40 mix of trans (Enclomiphene) and cis (Zuclomiphene). While enclomiphene (trans-clomiphene) is an estrogen antagonist, zuclomiphene (cis-clomiphene) is a mixed agonist, responsible for the estrogenic activity and therefore the common side effects sometimes seen in males. The enclomiphene isomer is responsible for the anti-estrogen activity and the restoration of ones hypothalamic–pituitary–gonadal axis. In recent clinical trials, enclomiphene increased serum LH and FSH with concomitant increases in testosterone in men with secondary hypogonadism. Enclomiphene showed overall better results than testosterone gels, which raise serum testosterone but can lower LH and FSH at the same time.
Inne uwagi
Light sensitive
Ta strona może zawierać tekst przetłumaczony maszynowo.
Fertility and sterility, 100(6), 1610-1614 (2013-10-01)
To determine whether there is a correlation between preovulatory endometrial stripe thickness (EST) and pregnancy rates in clomiphene citrate (CC)/IUI cycles. Retrospective cohort. Infertility clinic of an academic medical center. A total of 262 patients completed 562 transvaginal ultrasound-monitored CC/IUI
Perinatal period and adolescence are critical for brain development, which is the biological basis of an individual's sexual orientation and sexual behavior. In this study, animals were divided into two groups and their sexual orientations were observed: one group experienced
Fertility and sterility, 100(2), 341-348 (2013-07-03)
This committee opinion describes the use of clomiphene citrate, including indications, use, monitoring, and side effects. There is also a discussion of adjuvants and alternatives to clomiphene citrate therapy.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 29(9), 826-829 (2013-07-17)
To evaluate the ability of a combination of multiple ovarian reserve markers to predict ovarian stimulation response in polycystic ovary syndrome (PCOS). On cycle Day 3 of 75 infertile patients with PCOS, serum follicle stimulating hormone (FSH), luteinizing hormone (LH)
Clomiphene citrate (CC) is first line treatment in women with World Health Organization (WHO) type II anovulation and polycystic ovary syndrome (PCOS). Whereas 60% to 85% of these women will ovulate on CC, only about one half will have conceived
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
